Department of Radiotherapy, King George's Medical University, Lucknow, Uttar Pradesh, India.
Toxicology & Experimental Medicine Division, Central Drug Research Institute (CSIR), Lucknow, Uttar Pradesh, India.
Asian Pac J Cancer Prev. 2022 Feb 1;23(2):419-427. doi: 10.31557/APJCP.2022.23.2.419.
The presence of cancer stem-like cells within tumor microenvironment distinctly governs response to chemo-radiotherapy. The ALDH1 (Aldehyde dehydrogenase 1) has emerged as a cancer stem cell (CSC) marker in various tumors. The aim of the study was to examine the expression of ALDH1 in HNSCC patients undergoing radiotherapy to evaluate its correlation with clinicopathological parameter, treatment response and survival.
Expression of ALDH1 was evaluated by immunohistochemistry in 90 histopathologically confirmed HNSCC patients and 90 matched controls. The association between ALDH1 expression, clinicopathological parameters and treatment response was determined.
The immunohistochemistry results showed that ALDH1 was consistently expressed in all the HNSCC specimens although at different intensities. On the other hand, control specimens did not show similar expression of ALDH1. ALDH1 expression demonstrated statistically significant association with tumor size (p<0.001), lymph node status (p<0.001), stage (p<0.001), grade (p<0.001) and treatment response (p<0.001). Multivariate ordinal logistic regression analysis indicated alcohol and ALDH1 as an independent predictor of responsiveness to radiotherapy in HNSCC patients. Multivariate Cox regression analysis indicated that lymph node status (p=0.020), grade (p=0.006) and recurrence (p=0.002) were potential independent predictors of overall survival.
From previous studies, ALDH1 has been contemplated not only as a promising prognostic and diagnostic marker but also as a likely drug target. Our study gives new understanding regarding the association between ALDH1, cancer prognosis and radioresistance. Our findings suggest that ALDH1, lymph node status, grade and alcohol could be the viable targets for HNSCC and it also provides new prospects for radiotherapy sensitivity in HNSCC.
肿瘤微环境中癌症干细胞样细胞的存在明显影响化疗放疗的反应。ALDH1（醛脱氢酶 1）已成为各种肿瘤的癌症干细胞（CSC）标志物。本研究旨在检查接受放疗的 HNSCC 患者中 ALDH1 的表达，以评估其与临床病理参数、治疗反应和生存的相关性。
通过免疫组织化学方法在 90 例组织病理学证实的 HNSCC 患者和 90 例匹配对照中评估 ALDH1 的表达。确定 ALDH1 表达与临床病理参数和治疗反应之间的关系。
免疫组织化学结果显示，ALDH1 在所有 HNSCC 标本中均持续表达，尽管表达强度不同。另一方面，对照标本未显示类似的 ALDH1 表达。ALDH1 表达与肿瘤大小（p<0.001）、淋巴结状态（p<0.001）、分期（p<0.001）、分级（p<0.001）和治疗反应（p<0.001）均有统计学显著相关性。多变量有序逻辑回归分析表明，酒精和 ALDH1 是 HNSCC 患者对放疗反应的独立预测因子。多变量 Cox 回归分析表明，淋巴结状态（p=0.020）、分级（p=0.006）和复发（p=0.002）是总生存的潜在独立预测因子。
从以前的研究中可以看出，ALDH1 不仅被认为是一种有前途的预后和诊断标志物，而且还可能是一种潜在的药物靶点。我们的研究对 ALDH1、癌症预后和放射抵抗之间的关系有了新的认识。我们的研究结果表明，ALDH1、淋巴结状态、分级和酒精可能是 HNSCC 的可行靶点，也为 HNSCC 的放疗敏感性提供了新的前景。
Zotero 插件